Invention Grant
US08877938B2 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
有权
含有N-戊酰基-N - {[2' - （1H-四唑-5-基） - 联苯-4-基] - 甲基} - 缬氨酸和（2R，4S）-5-联苯-4-基-4 - （3-羧基 - 丙酰基氨基）-2-甲基 - 戊酸乙酯部分和阳离子
![Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations](/docs/US/2014-11-04/US08877938B2/abs.jpg.600x600.jpg)
- Patent Title: Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
- Patent Title (中): 含有N-戊酰基-N - {[2' - （1H-四唑-5-基） - 联苯-4-基] - 甲基} - 缬氨酸和（2R，4S）-5-联苯-4-基-4 - （3-羧基 - 丙酰基氨基）-2-甲基 - 戊酸乙酯部分和阳离子
-
Application No.: US11722360Application Date: 2006-11-08
-
Publication No.: US08877938B2Publication Date: 2014-11-04
- Inventor: Lili Feng , Sven Erik Godtfredsen , Bin Hu , Yugang Liu , Piotr Karpinski , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Thomas J. Blacklock
- Applicant: Lili Feng , Sven Erik Godtfredsen , Bin Hu , Yugang Liu , Piotr Karpinski , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Thomas J. Blacklock
- Applicant Address: US NJ East Hanover
- Assignee: Novartis Pharmaceuticals Corporation
- Current Assignee: Novartis Pharmaceuticals Corporation
- Current Assignee Address: US NJ East Hanover
- Agent Matthew Mulkeen
- International Application: PCT/US2006/043710 WO 20061108
- International Announcement: WO2007/056546 WO 20070518
- Main IPC: C07D257/04
- IPC: C07D257/04 ; C07C233/47 ; A61K31/41 ; A61K31/4422 ; A61K31/5415
![Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations](/abs-image/US/2014/11/04/US08877938B2/abs.jpg.150x150.jpg)
Abstract:
A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.
Public/Granted literature
- US20090156585A1 ORGANIC COMPOUNDS Public/Granted day:2009-06-18
Information query
